RESUMO
BACKGROUND: Metabolic syndrome (MS) increases the risk of heart disease, stroke, and other complications. AIM: The aim of this study was to assess the clinical and biochemical parameters of MS and its complications (cerebrovascular accidents, cardiovascular accidents, DN or chronic kidney disease (CKD) compared with healthy controls especially among the younger population in Northern India. MATERIAL AND METHODS: A total of 245 (healthy, MS and it's complicated) aged 18-70 years participated in the Open-Label, Single Centered; hospital-based random selection case-control comparative study. All anthropometric and biochemical assessment was done after proper consent. The metabolic syndrome was determined by IDF criteria. RESULTS: The key risk parameters in three groups i.e. Control, Metabolic syndrome, and Complicated was TG (96.5⯱â¯46.9, 194.1⯱â¯87.8, 148.0⯱â¯102.2). LDL (91.2⯱â¯27.2, 114.0⯱â¯31.8, 69.1⯱â¯42.5, BP (120.1⯱â¯9.9, 139.3⯱â¯13.3, 132.1⯱â¯15.0) and high fasting glucose (81.1⯱â¯13.7, 164.5⯱â¯84.3, 138.0⯱â¯74.5). The hs-CRP is also significantly increased in the complicated group. The subanalysis of data also indicates that younger middle age (36-55 years) group both male and female is obese, hypertensive, diabetic with lipid abnormality according to IDF criteria. CONCLUSION: The risk factors like high TG, low HDL, high BP, and high fasting glucose were found higher particularly in younger population which may lead to diagnosis & complications of diabetes, hypertension and lipid abnormality. Due to changing physiology in young and middle age population these individuals are moving towards metabolic syndrome easily and needs frequent monitoring, preventive checkups, and lifestyle changes to prevent complications.
Assuntos
Biomarcadores/análise , Doenças Cardiovasculares/etiologia , Transtornos Cerebrovasculares/etiologia , Diabetes Mellitus/etiologia , Síndrome Metabólica/complicações , Insuficiência Renal Crônica/etiologia , Adolescente , Adulto , Idoso , Antropometria , Doenças Cardiovasculares/metabolismo , Doenças Cardiovasculares/patologia , Estudos de Casos e Controles , Transtornos Cerebrovasculares/metabolismo , Transtornos Cerebrovasculares/patologia , Diabetes Mellitus/metabolismo , Diabetes Mellitus/patologia , Feminino , Seguimentos , Humanos , Lipídeos/análise , Masculino , Pessoa de Meia-Idade , Prognóstico , Insuficiência Renal Crônica/metabolismo , Insuficiência Renal Crônica/patologia , Adulto JovemRESUMO
INTRODUCTION: Hypertension, "The silent killer" is a multifactorial disorder which is asymptomatic and if left untreated leads to lethal complications. Nebivolol is a third generation beta blocker with additional vasodilating property due to nitric oxide release. AIM: The current study aims to assess efficacy and safety of Nebivolol and compare with Atenolol. METHODS: This was prospective, double blind, comparative controlled clinical study. Total 90 patients were enrolled into study as per selection criteria. Patients were randomized to receive Atenolol and Nebivolol with 45 patients in each group for 12 weeks. RESULTS AND CONCLUSION: The mean reduction diastolic blood pressure in Nebivolol and Atenolol group was 10.77±2.60 and 10.05±2.83 respectively. The number of patients with adverse effect events was higher in the Atenolol than in the Nebivolol group (36.84% of Atenolol Vs 12.82% of Nebivolol). Thus it can be concluded that, for the same antihypertensive effect, Nebivolol was better tolerated than Atenolol.
